Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma

Targeting the Tetraspanins with Monoclonal Antibodies in Oncology: Focus on Tspan8/Co-029

(2019) Mathilde Bonnet et al.   Cancers

Engineering and Design of Chimeric Antigen Receptors

(2019) Sonia Guedan et al.   Molecular Therapy-Methods & Clinical Development

Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting

(2019) Shivani Srivastava et al.   CANCER CELL

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

(2019) Stefan Stoiber et al.   Cells

TSPAN8 promotes cancer cell stemness via activation of sonic Hedgehog signaling

(2019) Rongxuan Zhu et al.   Nature Communications

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies

(2019) Xinjie Xu et al.   Frontiers in Immunology

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Towards understanding the mechanisms of actions of carcinoembryonic antigen-related cell adhesion molecule 6 in cancer progression

(2018) Balsam Rizeq et al.   CANCER SCIENCE

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

(2018) Matthew L Cooper et al.   LEUKEMIA

Therapeutic developments in pancreatic cancer: current and future perspectives

(2018) John P. Neoptolemos et al.   Nature Reviews Gastroenterology & Hepatology

FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation

(2018) Yan-Hong Cui et al.   ONCOGENE

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

(2018) Elena J. Orlando et al.   NATURE MEDICINE

The Potential of CAR T Cell Therapy in Pancreatic Cancer

(2018) Mehmet Akce et al.   Frontiers in Immunology

CEACAM6 is a prognostic biomarker and potential therapeutic target for gastric carcinoma

(2017) Guo-Qing Ru et al.   Oncotarget

Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy

(2016) Mark O'Hara et al.   Immunotherapy

Patient-derived xenografts: a relevant preclinical model for drug development

(2016) Luca Pompili et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease

(2016) Jianchun Chen et al.   PHYSIOLOGICAL REVIEWS

Versatile strategy for controlling the specificity and activity of engineered T cells

(2016) Jennifer S. Y. Ma et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts

(2016) M Cartellieri et al.   Blood Cancer Journal

Fine-tuning the CAR spacer improves T-cell potency

(2016) Norihiro Watanabe et al.   OncoImmunology

Pancreatic cancer

(2016) Jorg Kleeff et al.   Nature Reviews Disease Primers

Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review

(2016) Vincent Muturi-Kioi et al.   PLoS One

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

(2015) H. G. Caruso et al.   CANCER RESEARCH

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

(2015) S. C. Katz et al.   CLINICAL CANCER RESEARCH

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Whole genomes redefine the mutational landscape of pancreatic cancer

(2015) Nicola Waddell et al.   NATURE

Tissue-based map of the human proteome

(2015) M. Uhlen et al.   SCIENCE

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

(2015) Agnieszka K. Witkiewicz et al.   Nature Communications

Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane

(2014) S. E. James et al.   JOURNAL OF IMMUNOLOGY

A draft map of the human proteome

(2014) Min-Sik Kim et al.   NATURE

Mass-spectrometry-based draft of the human proteome

(2014) Mathias Wilhelm et al.   NATURE

CEACAM6 Promotes Gastric Cancer Invasion and Metastasis by Inducing Epithelial-Mesenchymal Transition via PI3K/AKT Signaling Pathway

(2014) Mingde Zang et al.   PLoS One

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

MUC1: a multifaceted oncoprotein with a key role in cancer progression

(2014) Sritama Nath et al.   TRENDS IN MOLECULAR MEDICINE

Tspan8, CD44v6 and alpha6beta4 are biomarkers of migrating pancreatic cancer-initiating cells

(2013) Haobin Wang et al.   INTERNATIONAL JOURNAL OF CANCER

CDCP1 Regulates the Function of MT1-MMP and Invadopodia-Mediated Invasion of Cancer Cells

(2013) Yuri Miyazawa et al.   MOLECULAR CANCER RESEARCH

Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy

(2013) Gwendlyn Kollmorgen et al.   Molecular Oncology

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

(2013) E. Lanitis et al.   Cancer Immunology Research

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

(2012) Scott Wilkie et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

(2012) Christopher C Kloss et al.   NATURE BIOTECHNOLOGY

Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software

(2011) Lee Kamentsky et al.   BIOINFORMATICS

Roles of CUB domain-containing protein 1 signaling in cancer invasion and metastasis

(2011) Takamasa Uekita et al.   CANCER SCIENCE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

E-Cadherin/p120-Catenin and Tetraspanin Co-029 Cooperate for Cell Motility Control in Human Colon Carcinoma

(2010) C. Greco et al.   CANCER RESEARCH

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

(2010) Maria R Parkhurst et al.   MOLECULAR THERAPY

The cell surface glycoprotein CDCP1 in cancer-Insights, opportunities, and challenges

(2009) Andreas Wortmann et al.   IUBMB LIFE

Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma

(2008) Yasuo Awakura et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY